Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
May 2004

Copper Perturbation in 2 Monozygotic Twins Discordant for Degree of Cognitive Impairment

Author Affiliations

From the Departments of Neuroscience (Drs Squitti, Cassetta, Dal Forno, Lippolis, Pauri, Vernieri, Cappa, and Rossini) and Radiology (Dr Lupoi), Associazione Fatebenefratelli per la Ricerc Foundation, Ospedale Fatebenefratelli, Rome, Italy; Clinica Neurologica, Università Campus Biomedico, Rome (Drs Dal Forno and Rossini); Departments of Neurology and Otolaryngology, Università "La Sapienza," Rome (Dr Pauri); and Istituto di Ricovero e Cura a Carattere Scientifico "Centro S. Giovanni di Dio-Fatebenefratelli," Brescia, Italy (Dr Rossini).


Copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2004

Arch Neurol. 2004;61(5):738-743. doi:10.1001/archneur.61.5.738

Background  Recent evidence indicates that peripheral tissue markers can provide information regarding changes affecting cellular metabolism in Alzheimer disease (AD). We previously reported that serum copper levels can discriminate subjects with AD from normal control subjects (with 60% sensitivity and 95% specificity) and from patients with vascular dementia (with 63% sensitivity and 85% specificity).

Objective  To study the correlation between AD and serum levels of transition metals and markers of peripheral oxidative stress.

Design  Case study.

Setting  General hospital inpatient wards and outpatient clinics.

Patients  A pair of elderly monozygotic female twins discordant for AD.

Main Outcome Measures  Biochemical analyses of peripheral-blood transition metals and indicators of oxidative stress and neurologic and neuropsychological assessments of clinical status for presence of cognitive impairment and AD.

Results  Serum copper and total peroxide levels were both 44% higher in the twin with greater cognitive impairment and a diagnosis of AD.

Conclusions  The cases reported support the hypothesis of a major involvement of copper and oxidative abnormalities in AD.

Alzheimer disease (AD) is a heterogeneous neurodegenerative condition, and biomarker research has focused on a variety of possible disease-related mechanisms.1 Among these, the depletion of vitamins with direct or indirect antioxidant effects and the increase in homocysteine and in compounds involved in lipid peroxidation are thought to reflect oxidative changes with a potential pathogenetic significance in AD, according to the oxidative stress hypothesis of this condition.24 Abnormalities of trace metal metabolism also seem to be a primary neurochemical event in the genesis and progression of the disease.5,6 We have previously reported that copper levels measured in the peripheral circulation discriminate between patients with AD and normal control subjects,7,8 as well as patients with vascular dementia.9

In this study, we compare putative markers of oxidative stress in a pair of 73-year-old female monozygotic twins discordant for AD, and we discuss the potential role of copper abnormalities in the pathogenesis of AD in agreement with proposed models of biometal-related neurodegeneration.6


The subjects studied were twin sisters (twins A and B) who underwent clinical evaluations, including comprehensive personal medical and family histories, psychiatric and neurologic examinations, extensive neuropsychological testing, and neuroimaging (magnetic resonance [MR] imaging or computed tomography [CT]), as well as routine laboratory tests. The neuropsychological evaluation included the Mini-Mental State Examination,10 the Mental Deterioration Battery,11 the Digit Span,12 and the Corsi test.12 The Mental Deterioration Battery provides scores on several cognitive domains: verbal and visuospatial skills, memory, constructive praxis, language, and logical-deductive skills. The battery consists of a number of subtests: 4 performance scores derived from verbally presented stimuli (the Rey Auditory Verbal Learning Test, 15-word immediate and delayed recall, verbal fluency, and sentence construction) and 3 from visuospatial processing tests (Raven Colored Progressive Matrices Test, Immediate Visual Memory, and Copying Drawings with and without landmarks). In addition, the Digit Span was administered to test immediate verbal memory,12 and the Corsi test for visuospatial short-term memory.12 All tests were corrected, where appropriate, for age, sex, and education.

Brain MR imaging was performed with a 1.5-T scanner (Philips Intera, Best, the Netherlands). Conventional dual-echo fast spin-echo images were obtained (T1-weighted and T2-weighted sequences), with and without contrast. The CT scans were obtained on a multislice CT scanner (Aquilon, MULTI; Toshiba Corporation, Shimoishigami, Japan) without contrast administration.

The common carotid arteries, carotid bifurcations, internal carotid arteries, and vertebral arteries were studied with B-mode duplex sonography (7.5-MHz probe; Acuson, Aspen, Colo) according to standardized criteria13,14 for presence of atherosclerotic plaques and degree of stenosis. Intima and media thickness was also studied from the distal portion of the common carotid artery, 1 cm proximal to the carotid bulb, as the mean value of 3 repeated measures of the intima and media thickness at the far wall of each common carotid artery.15 Intracranial vessels were examined by transcranial Doppler (Multidop T TCD-DWL; DWL Elektronische Systeme GmbH, Sipplingen/Bodensee, Germany). Arteries of the circle of Willis were studied according to previously described methods, measuring mean flow velocities in the anterior, middle, and posterior cerebral arteries to exclude intracranial stenosis.16

Electroencephalograms were obtained with a digital electroencephalographer (Galileo; EBNeuro, Firenze, Italy) according to standard clinical procedures and the international 10-20 system for electrode placement (0.1- to 125-Hz bandpass; linked-ear reference).

Laboratory tests included a complete blood cell count; erythrocyte sedimentation rate; serum protein electrophoresis; levels of ferritin, fibrinogen, serum creatinine, serum urea nitrogen, fasting glucose, electrolytes, vitamin B12, folic acid, and uric acid; thyroid function tests (thyroxine, triiodothyronine, and thyrotropin levels); liver enzyme (aspartate aminotransferase and alanine aminotransferase) and bilirubin levels; serologic tests for syphilis and urinalysis. Both patients had a standard electrocardiogram.

The study was approved by the local institutional review board; both subjects signed an informed consent.


Serum from fasting blood samples was collected in the morning and rapidly stored at −80°C. Other blood samples using EDTA as anticoagulant were drawn for DNA extraction and total plasma homocysteine determination. Measurements of biological variables of oxidative stress and trace metals are described in detail elsewhere.8

Briefly, serum copper concentration was measured both with the method of Abe et al17 (Randox Laboratories, Crumlin, England) and by an atomic absorption spectrophotometer (A Analyst 300; PerkinElmer Inc, Boston, Mass) equipped with a graphite furnace with platform (HGA 800; PerkinElmer Inc). 8 Intra-assay coefficient of variation (CV) on 20 aliquots of fresh serum and interassay CV evaluated on 20 aliquots of frozen serum were calculated in our laboratory for the Abe method for copper estimation as well as for measurement of total peroxides and total radical trapping antioxidant capacity (TRAP) assay. Intra-assay CV for copper was 2.45%, while interassay CV was 3%. Hydroperoxide and lipoperoxide content was assessed by spin trap N,N-diethyl-para-phenylendiamine method (d-ROMs; Diacron, Grosseto, Italy)18 and expressed in arbitrary units (U CARR; 1 U CARR corresponds to 0.08 mg/100 mL of hydrogen peroxide)18; intra-assay CV was 2.5%, while interassay CV was 3.3%. Reference values reported by the manufacturer were between 250 and 300 U CARR.1820 The TRAP assay is based on the quenching of the radical cation 2′2-azinobis-(3-ethyl-benzothiazoline-6-sulfonic acid) by the total antioxidants present in serum (TAS; Randox Laboratories)21,22 (see Squitti et al8 for details). The manufacturer's serum reference range is 8.28 to 11.27 µg/dL (1.30-1.77 mmol/L)22; intra-assay CV of 1.95% and interassay CV of 3.1% were calculated in our laboratory. Serum iron level was determined by a colorimetric method (FerroZine; Roche Diagnostics, Mannheim, Germany).23,24 Transferrin was estimated by immunoturbidimetric assays (Roche Diagnostics) with the use of a goat anti–human transferrin antibody in Tris hydrochloride buffer.

All biochemical measures were obtained on an automated analyzer (Hitachi 917; Roche Diagnostics). Total homocysteine was assayed by high-performance liquid chromatography on plasma samples in EDTA.25 All biochemical measurements were performed in triplicate, matched within the twin pair, and compared by z-score analysis, with reference values obtained from a healthy elderly population not affected by pathologic conditions able to alter copper metabolism or peripheral oxidative stress (eg, diabetes mellitus; inflammatory diseases; cardiac, respiratory, liver, or renal insufficiency; malignant tumors; and alcohol abuse).7,8 Apolipoprotein E (APOE) genotyping was performed according to established methods.26 For determination of zygosity, 10 highly polymorphic DNA sequences (3 located within genes TH01, FGA, and vWA and 7 in anonymous segments D2S1338, D3S1358, D8S1179, D16S539, D18S51, D19S433, and D21S11) were amplified by polymerase chain reaction with fluorescent-labeled primers and analyzed by capillary electrophoresis (ABI Prism Genetic Analyzer 310; PE Biosystems Foster City, Calif). Genotypes were determined by means of a software package (Genotyper 2.5; Applied Biosystems, Foster City). Concordance for all 10 loci predicts monozygosity with greater than 99.98% probability, regardless of the allelic pattern observed (calculations based on allele frequencies observed in 4 major racial groups, University of Utah DNA Diagnostic Laboratory, Salt Lake City).27

Twin A

A 73-year-old woman was admitted to the hospital in June 2000 because of purposeless wandering and poor self-care in the context of progressive cognitive impairment. The insidious onset of slowly progressive memory impairment and cognitive decline dated back 5 years before hospitalization.

Medical history was pertinent for hypertension, chronic atrial fibrillation, and early menopause at age 45 years. The patient had never received estrogen therapy. Her medications included digoxin, enalapril maleate, verapamil hydrochloride, and aspirin. Family history was reportedly negative for dementing illnesses or strokes.

The patient underwent a comprehensive clinical evaluation including psychiatric and neurologic examinations. Results of laboratory tests were within normal limits. The patient refused to undergo brain MR imaging. A head CT scan showed enlarged cortical sulci and lateral ventricles (diffuse atrophy) and mild hypodensity of the white matter (Figure 1). Echo color duplex scanning of the cerebral vessels and intracranial blood flow velocities did not show any hemodynamically significant alteration. Electroencephalogram showed diffuse background slowing of alpha rhythms, most prevalent over the frontal regions. There was no clinical evidence of depression. Neuropsychological testing showed short- and long-term deficits in both visual and verbal memory function, impairment of executive function, poor constructional skills, and difficulties in accessing semantic storage by means of phonemic cues (Table 1). The patient met criteria of the National Institute of Neurological Diseases and Stroke–Alzheimer's Disease and Related Diseases Association for probable Alzheimer disease.28 Shortly after hospital discharge and after voluntarily discontinuing her medications, the patient died of cardiac failure.

Figure 1.
Image not available

Axial noncontrast computed tomographic scan of the brain in twin A showing enlargement of the lateral ventricles and cortical sulci and diffuse hypodensity of the white matter.

Table 1. 
Image not available
Results of Neuropsychological Tests for Twin A and Twin B*
Twin B

The patient was admitted to the hospital for an episode of transient aphasia and right-upper-extremity paresis in November 1999. She was 73 years old in June 2000 when she consented to undergo clinical evaluations, including neuropsychological and biological assessment, for comparison with her sister. Medical history was pertinent for hypertension and myocardial infarction. Her medications included warfarin sodium, sotalol hydrochloride, and verapamil. She had received estrogen therapy for 1 year at menopause (45 years of age). Brain MR imaging showed a subacute infarction of the left occipital lobe in the left posterior cerebral artery territory and hyperintense areas in the frontal white matter (consistent with chronic small-vessel ischemic lesions) (Figure 2A and B). The neuropsychological performance of twin B was repeatedly assessed over 3 years (Table 1). At the time of her hospital admission, she showed both long- and short-term verbal memory deficits and a Mini-Mental State Examination score of 29. A year later she demonstrated only a slight impairment of both verbal and spatial span. In the third-year testing she had a Mini-Mental State Examination score of 30 and only a minor long-term verbal memory deficit with impaired free recall and normal recognition, suggesting intact encoding, but abnormal retrieval, possibly of cerebrovascular origin. Twin B did not meet criteria for diagnosis of dementia at any point during the 4 years of follow-up and actually showed cognitive improvement over time (Table 1).

Figure 2.
Image not available

Brain magnetic resonance images of twin B. A, T2-weighted axial image demonstrating T2 prolongation in the left occipital cortex and white matter. B, Axial T1-weighted image showing an area of linear enhancement of cortical and subcortical white matter after contrast administration. C, T2-weighted image showing small areas of prolonged T2 in the left frontal white matter consistent with chronic infarctions.

Carotid duplex ultrasound scans showed a bilateral 50% stenosis of the internal carotid artery. The electroencephalogram was abnormal at the time of the stroke because of focal left temporal slowing, as is often observed in normal aging.29 Results of screening laboratory tests were normal.

Both twins had smoked approximately 25 cigarettes per day since youth, had completed 2 years of high school, had worked as office clerks, had never been married, and had lived together all their lives, therefore sharing a very similar lifestyle.


Measurements of copper, total peroxides, TRAP, iron, and transferrin in serum, and total plasma homocysteine levels, are reported in Table 2. For either twin, analysis of the z scores indicated no abnormalities with respect to reference values for TRAP, iron, and transferrin levels. For twin A's copper and total peroxide levels, instead, the z-score units were above the reference range mean. Twin B's serum copper level was borderline, while total peroxide levels were higher than reference values. Twin A had a 44% increment in both copper and peroxide concentrations compared with her twin sister. Total plasma homocysteine level did not differ between the twins, but it was higher than reference values. A correlation between degree of cerebral cortical atrophy and biochemical markers could not be performed because of the use of different imaging procedures (CT scan in twin A and MR imaging in twin B). The APOE genotype was ϵ3/ϵ3.

Table 2.  
Image not available
Comparison of Trace Metals and Oxidative Stress Species Assessed in June 2000 in Both Twins*7,8,17

The cases presented in this study, with a clinical picture of 2 identical twins discordant for AD but with very similar habits and lifestyle, provide information about the role of copper and oxidative dysfunction. This is therefore a good opportunity to study environmental and lifestyle factors that could affect individual antioxidant efficiency and oxidative stress markers in AD. Differences in antioxidant capacity due to both epigenetic and genetic factors could in fact be responsible for the variations in serum concentrations of oxidative indicators observed in subgroups of patients with AD, or for the overlap that has been often noted between patients and normal controls.1 The main finding in the study of this twin pair is that differences in copper levels corresponded to a different clinical picture, in agreement with our previous reports.7,8 The patient who had greater serum levels of copper and oxidative stress indicators, twin A, had overall worse scores on all cognitive testing and met criteria for a diagnosis of AD. Her twin sister, whose levels were much lower, yet slightly increased compared with normal, remained free of dementia 4 years after her sister's death and after the initial stroke that brought her to our attention. Only a longitudinal follow-up of the surviving twin will eventually determine whether she will also develop dementia. Currently, all evidence suggests that her minor cognitive deficits are on a vascular basis. Both women had a number of common vascular risk factors, including heavy smoking and early menopause. Twin A also had atrial fibrillation, even though she had no clinical or neuroimaging evidence of any significant cerebrovascular impairment. Twin B, compared with her sister, had instead a significant vascular burden, which appeared to be the major determinant of her mild cognitive deficits of a focal cortical dysfunction consistent with the location of her infarcts. Interestingly, previous work from our group had shown that cerebrovascular dysfunction has little impact on serum copper variations,7,9 and the cases presented herein support this view.

We detected no differences in iron metabolism between the twins and in relation to normal reference values. Likewise, TRAP capacity, an index of oxidative stress susceptibility, did not differ within the twin pair. The twins were negative for the presence of the genetic susceptibility risk factor APOEϵ4allele. Both twins had elevation of their homocysteine levels, a known risk factor for cardiovascular and cerebrovascular disease.30,31 Homocysteine levels therefore appeared independent of cognitive status. Total peroxide levels, instead, were associated with the presence of cognitive impairment and, in particular, with presence of dementia, since they were more elevated in the twin with AD. This finding is consistent with published evidence of increments in F2-isoprostane, hydrogen peroxide, and lipoperoxidation products in brains of patients with AD.7,3235 However, we have previously shown that elevation of peroxide levels, though present in dementia, is not specific for AD.7,9 Conversely, copper elevation, as also noted in this study, appears to be specific for AD, in agreement with previous findings on trace metals and oxidative species differences in patients with AD compared with healthy controls7,36 and patients with vascular dementia.9 The twin diagnosed as having AD had a serum copper concentration much higher than the cutoff level of 101.9 µg/dL (16 µmol/L), adopted to positively separate patients with AD from normal controls.7 Even though a single recent report did not show copper elevation in AD,37 our current results strengthen the notion that studying copper in living patients could add useful information on the pathogenesis of AD.7,9

The copper abnormalities described herein seem to further support the proposed model of a major role of biometals in the pathogenesis of AD.6 According to this hypothesis, stochastic neurochemical events, such as the oxidation of β-amyloid (Aβ) peptide or a rise in copper or iron level, may cause a small population of Aβ to convert to a rogue form with adverse redox reactivity, responsible for hydrogen peroxide production and Aβ aggregation in plaques.6 The Aβ combines with ionic copper to form a catalytic complex that generates hydrogen peroxide.38 Hydrogen peroxide is freely permeable, and its generation from the brain amyloid mass into the blood of the cerebral blood vessels might elevate blood peroxide levels.

It is noteworthy that the twins in this study, despite their identical genetic makeup and exceedingly similar life experiences, differed in estrogen exposure. In fact, twin B, unlike her twin sister, had had a full-term pregnancy as well as estrogen therapy after menopause. Although no conclusions can be drawn from a single twin pair, this observation is in line with the yet controversial body of literature on the protective role of estrogens against dementia.3942 Discordance for presence of AD in identical twin pairs differing in estrogen exposure has already been reported.43 If estrogen exposure does indeed modify the risk of AD by delaying its onset, the discordance in AD onset and copper levels in the twin pair herein described could be at least partly explained. To determine whether copper could be considered a suitable "marker" for AD, as suggested by this and other previous reports,7,8,36 more extensive studies are needed.


The present study shows that differences in copper levels corresponded to a different clinical picture in a monozygotic twin pair. The case reported, along with previous descriptions of twin pairs in the literature, is useful not to prove a putative cause or risk factor but, instead, to generate discussion about hypotheses of environmental, lifestyle, and in general stochastic neurochemical events causative of or protective from disease.

Back to top
Article Information

Corresponding author: Rosanna Squitti, PhD, Department of Neuroscience, AFaR, Ospedale Fatebenefratelli, Isola Tiberina, 00186, Rome, Italy (e-mail:

Accepted for publication September 12, 2003.

Author contributions: Study concept and design (Drs Squitti, Dal Forno, and Rossini); acquisition of data (Drs Squitti, Cassetta, Lupoi, Lippolis, Pauri, Vernieri, and Cappa); analysis and interpretation of data (Drs Squitti, Dal Forno, and Rossini); drafting of the manuscript (Drs Squitti, Dal Forno, Lupoi, Vernieri, and Rossini); critical revision of the manuscript for important intellectual content (Drs Cassetta, Dal Forno, Lippolis, Pauri, Vernieri, Cappa, and Rossini); obtained funding (Drs Squitti, Cassetta, Pauri, and Rossini); administrative, technical, and material support (Drs Squitti, Pauri, and Rossini); study supervision (Drs Squitti, Dal Forno, and Rossini); radiological expertise (Dr Lupoi); neuropsychological expertise (Drs Lippolis and Cappa); technical expertise (Dr Vernieri).

This investigation was supported by grants RF 0053 and RF 6/00 from the Italian Ministero della Salute (Ricerca Finalizzata "Malattia di Alzheimer: studio del rischio legato a fattori lavorativi"), Rome, Italy, and by a grant from Associazione Fatebenefratelli per la Ricerc Foundation, Ospedale Fatebenefratelli, Rome.

Teunissen  CEde Vente  JSteinbusch  HWDe Bruijn  C Biochemical markers related to Alzheimer's dementia in serum and cerebrospinal fluid. Neurobiol Aging.2002;23:485-508.
Pratico  DClark  CMLee  VMTrojanowski  JQRokach  JFitzGerald  GA Increased 8,12-iso-iPF2alpha-VI in Alzheimer's disease: correlation of a noninvasive index of lipid peroxidation with disease severity. Ann Neurol.2000;48:809-812.
Pratico  DUryu  KLeight  STrojanoswki  JQLee  VM Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. J Neurosci.2001;21:4183-4187.
Markesbery  WR Oxidative stress hypothesis in Alzheimer's disease. Free Radic Biol Med.1997;23:134-147.
Cuajungco  MPFaget  KY Zinc takes center stage: its paradoxical role in Alzheimer's disease. Brain Res Rev.2003;41:44-56.
Bush  AI Metal complexing agents as therapies for Alzheimer's disease. Neurobiol Aging.2002;23:1031-1038.
Squitti  RLupoi  DPasqualetti  P  et al Elevation of serum copper levels in Alzheimer's disease. Neurology.2002;59:1153-1161.
Squitti  RRossini  PMCassetta  E  et al D-penicillamine reduces serum oxidative stress in Alzheimer's disease patients. Eur J Clin Invest.2002;32:51-59.
Squitti  RPasqualetti  PCassetta  E  et al Elevation of serum copper levels discriminates Alzheimer's disease from vascular dementia. Neurology.2003;60:2013-2014.
Folstein  MFFolstein  SEMcHugh  PR "Mini-Mental State": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res.1975;12:189-198.
Carlesimo  GACaltagirone  CGainotti  GGroup for the Standardization of the Mental Deterioration Battery The Mental Deterioration Battery: normative data, diagnostic reliability and qualitative analyses of cognitive impairment. Eur Neurol.1996;36:378-384.
Orsini  AChiacchio  LCinque  MCocchiaro  CSchiappa  OGrossi  D Effects of age, education and sex on two tests of immediate memory: a study of normal subjects from 20 to 99 years of age. Percept Mot Skills.1986;63:727-732.
Von Reutern  GMBüdingen  HJeds   Ultrasound Diagnosis in Cerebrovascular Disease.  Stuttgart, Germany: Georg Thieme Verlag; 1989.
Bartels  Eed   Color-Coded Duplex Ultrasonography of the Cerebral Vessels: Atlas and Manual.  Stuttgart, Germany: Schattauer; 1999.
O'Leary  DHPolak  JFKronmal  RAManolio  TABurke  GLWolfson Jr  SKCardiovascular Health Study Collaborative Group Carotid-artery intima media thickness as a risk factor for myocardial infarction and stroke in older adults. N Engl J Med.1999;340:14-22.
Aaslid  RMarkwalder  TMNornes  H Noninvasive transcranial Doppler ultrasound recording of flow velocity in basal cerebral arteries. J Neurosurg.1982;57:769-774.
Abe  AYamashita  SNoma  A Sensitive, direct colorimetric assay for copper in serum. Clin Chem.1989;35:552-554.
Alberti  ABolognini  LMacciantelli  DCarratelli  M The radical cation of N,N-diethyl-para-phenylendiamine: a possible indicator of oxidative stress in biological samples. Res Chem Intermed.2000;26:253-267.
Trotti  RCarratelli  MBarbieri  M  et al Oxidative stress and a thrombophilic condition in alcoholics without severe liver disease. Haematologica.2001;86:85-91.
Cesarone  MRBelcaro  GCarratelli  M  et al A simple test to monitor oxidative stress. Int Angiol.1999;18:127-130.
Rice-Evans  CMiller  NJ Total antioxidant status in plasma and body fluids. Methods Enzymol.1994;234:279-293.
Miller  NJRice-Evans  CDavies  MJGopinathan  VMilner  A A novel method for measuring antioxidant capacity and its application to monitoring the antioxidant status in premature neonates. Clin Sci.1993;84:407-412.
Siedel  JWahlefeld  AWZiegenhorn  J A new iron ferrozine reagent without deproteinization [abstract]. Clin Chem.1984;30:975.
Wick  MPinggera  WLehmann  Peds   Iron Metabolism Diagnosis and Therapy of Anemias. 3rd ed. Vienna, Austria: Springer-Verlag; 1996.
Accinni  RCampolo  JBartesaghi  S  et al High-performance liquid chromatographic determination of total plasma homocysteine with or without internal standards. J Chromatogr A.1998;828:397-400.
Hixson  JEVernier  DT Restriction isotyping of human APOE by gene amplification and cleavage with HhaI. J Lipid Res.1990;31:545-548.
Anderson  JHChristova  PSXie  TDSchott  KSWard  KGomez  CM Spinocerebellar ataxia in monozygotic twins. Arch Neurol.2002;59:1945-1951.
McKhann  GDrachman  DFolstein  MKatzman  RPrice  DStadlan  EM Clinic diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's disease. Neurology.1984;34:939-944.
Kooi  KAYamada  TMarshall  RE Field studies of monocularly evoked cerebral potentials in bitemporal hemianopsia. Neurology.1973;23:1217-1225.
Clarke  RDaly  LRobinson  K  et al Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med.1991;324:1149-1155.
Refsum  HUeland  PMNygard  OVollset  SE Homocysteine and cardiovascular disease. Annu Rev Med.1998;49:31-62.
Nourooz-Zadeh  JLiu  EHYhlen  BAnggard  EEHalliwell  B F4-isoprostanes as specific marker of docosahexaenoic acid peroxidation in Alzheimer's disease. J Neurochem.1999;72:734-740.
Subbarao  KVRichardson  JSAng  LC Autopsy samples of Alzheimer's cortex show increased peroxidation in vitro. J Neurochem.1990;55:342-345.
Ramassamy  CAverill  DBeffert  U  et al Oxidative damage and protection by antioxidants in the frontal cortex of Alzheimer's disease is related to the apolipoprotein E genotype. Free Radic Biol Med.1999;27:544-553.
Lovell  MAEhmann  WDButler  SMMarkesbery  WR Elevated thiobarbituric acid–reactive substances and antioxidant enzymes activity in the brain in Alzheimer's disease. Neurology.1995;45:1594-1601.
Gonzalez  CMartin  TCacho  J  et al Serum zinc, copper, insulin, and lipids in Alzheimer's disease epsilon 4 apolipoprotein E allele carriers. Eur J Clin Invest.1999;29:637-642.
Ozcankaya  RDelibas  N Malondialdehyde, superoxide dismutase, melatonin, iron, copper and zinc blood concentrations in patients with Alzheimer disease: cross-sectional study. Croat Med J.2002;43:28-32.
Opazo  CHuang  XCherny  RA  et al Metalloenzyme-like activity of Alzheimer's disease β-amyloid: Cu-dependent catalytic conversion of dopamine, cholesterol and biological reducing agents to neurotoxic H2O2J Biol Chem.2002;277:40302-40308.
Fillit  HM The role of hormone replacement therapy in the prevention of Alzheimer disease. Arch Intern Med.2002;162:1934-1942.
Garcia-Segura  LMAzcoitia  IDon Carlos  LL Neuroprotection by estradiol. Prog Neurobiol.2001;63:29-60.
Behl  CMoosmann  B Antioxidant neuroprotection in Alzheimer's disease as preventive and therapeutic approach. Free Radic Biol Med.2002;33:182-191.
Shumaker  SALegault  CRapp  SR  et al Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA.2003;289:2651-2662.
Small  GWLeuchter  AFMandelkern  MA  et al Clinical, neuroimaging and enviromental risk differences in monozygotic female twins appearing discordant for dementia of the Alzheimer type. Arch Neurol.1993;50:209-219.